AI assistant
Easyjet PLC — Regulatory Filings 2018
Jul 5, 2018
5295_bfr_2018-07-05_dcd6c847-005a-48aa-a508-b70d38cba35f.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 6554T
easyJet PLC
05 July 2018
5 July 2018
EASYJET PASSENGER STATISTICS JUNE 2018*
| Month ending | June 2018 | June 2017 | Change |
| Passengers 1 | 7,901,285 | 7,720,090 | 2.3% |
| Load Factor 2 | 95.4% | 94.8% | 0.5pp |
| Rolling 12 months ending | June 2018 | June 2017 | Change |
| Passengers 1 | 83,273,673 | 78,114,520 | 6.6% |
| Load Factor 2 | 93.5% | 92.1% | 1.5pp |
*The passenger statistics above do not include Tegel operations.
There were 1,263 cancellations in June 2018 - equivalent to c.2.7ppts of planned capacity and up on the 213 experienced in June 2017. Around 900 were due to French and Italian industrial action with a further 150 arising from ATC restrictions and adverse weather conditions.
Enquiries should be directed to:
easyJet plc
| Investor: | |
| Stuart Morgan | +44 (0) 7989 665 484 |
| Michael Barker | +44 (0) 7985 890 939 |
| Media: | |
| Anna Knowles, Communications | +44 (0) 7985 873 313 |
1. Represents the number of earned seats flown. Earned seats include seats that are flown whether or not the passenger turns up because easyJet is a no-refund airline, and once a flight has departed a no-show customer is generally not entitled to change flights or seek a refund. Earned seats also include seats provided for promotional purposes and to staff for business travel.
2. Represents the number of passengers as a proportion of the number of seats available for passengers. No weighting of the load factor is carried out to recognise the effect of varying flight (or "stage") lengths.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
UPDGMGGNMDLGRZZ